FDA advisory committee to review GRAIL's Galleri multi-cancer early detection test
GRAIL has announced that an FDA advisory committee will review the premarket approval (PMA) application for its Galleri multi-cancer early detection test. The test analyzes the methylome, and AI plays a growing role in the evaluation.
Who is affected and how
- doctor
- The authorization decision on multi-cancer screening tests may shape screening recommendations and patient information.
- medtech company
- The Galleri review is a precedent for the PMA pathway of similar AI-driven diagnostic tests.
Sources
- GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Testprnewswire.com · Aug 7, 2026
- This New AI Cancer Detection Tool Just Got FDA Approval — Here's What It Means For You - The Edvocatetheedadvocate.org · Aug 7, 2026
- Too good to be true? This new blood test reportedly detects several types of cancer | EgészségKalauzegeszsegkalauz.hu · Aug 8, 2026 · magyar
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.